Have Brain; Will Travel

Join the Adventure and You Could Win 500 USD-Contest begins September 2015. Monthly winners receive 100 USD. Contest will run for 6 months. Grand prize is 500 USD.

Join Neuromics on our‪#‎BrainAdventure‬ to see all the interesting and unique locations the brain ventures. Starting this September, with all orders, you will receive a Neuromics brain keychain. Take a creative picture or short video of the Neuromics Brain Keychain and tweet it @Neuromics, post it on Neuromics Facebook or LinkedIn Page and be entered in our contest. In the meantime, if you want to join the contest, e-mail rose@neuromics.com and she will mail you your brain.

Here’re some examples:

We would welcome your participation!

The Dance Between Immune System and Stem Cell Health

We named it the  immunoLinkTM 
We have been testing a growing number of Clients with our Quantibody Arrays. Many of of these clients have Autoimmune Disorder Diseases. These range from Rheumatoid Arthritis to Multiple Sclerosis.

These arrays are designed to precisely measure factors or markers(proteins) that are dysregulated by these diseases. We measure the levels of these biomarkers in our Clients’ Blood serum. The arrays have also been used to measure the levels of markers in plasma and cell culture supernatants.

Based on results, we are finding links between immune system and stem cell health. We call this the immunoLink. The link shows that when immune/inflammatory response markers are elevated, markers related to stem cell health are depleted.

Here we see the immune/inflammatory response markers IL-6, MCP-1 and TNF-alpha are elevated in our Clients with autoimmunity (A) vs Healthy Controls (HC). We also see lower levels of G-CSF and GM-CSF in these Clients.

G-CSF and GM-CSF are know to play a role in increasing circulating stem cells. GM-CSF is also know to be secreted by Mesenchymal Stem Cells (hMSCs) AND GM-CSF has anti-apoptotic functions on neurons, and is neuroprotective in animal stroke models while G-CSF has a prominent effect on the differentiation of adult neural stem cells (see: BMC Neuroscience 2007, doi:10.1186/1471-2202-8-88).

To us, the immunoLink means achieving a balance between immune system and stem cell health.

We provide immune system balancing and stem cell activating therapies for our Autoimmune Disease Clients and Children with Autism. We first do baseline and follow on testing (each 6 months) to determine how well the therapies are working. You can now benefit from one of our first Stem Cell Activating Product named Stem-Kine.

Dr. Joe Smarda, an applied immunologist, is user and promoter of Stem-Kine and oh, by the way. He is a European Porsche Cup Champion and pilots our Stem-Kine/Neuromics sponsored race car.

Our goal is to bring the many markers we test to healthier levels. As stem cell transplants become more common, moderating levels of immune/inflammatory response in patients could improve outcomes. If you would like to learn more, you can contact me at pshuster@neuromics.com or 612-801-1007.

Treating Autism and TBI

I am excited about this important development in the Neuromics and Vitro Biopharma partnership: We are in the planning stages of clinical trials to test mobilization of endogenous stem cells in the treatment of traumatic brain injury and Autism Spectrum Disorders. This is based on substantial pre-clinical research suggesting that activation of certain cellular pathways in combination with epigenetic modulation of select gene expression yields increased proliferation, migration and differentiation of adult stem cells including neural stem cells and MSCs.
See Press Release: http://finance.yahoo.com/news/vitro-biopharma-revenues-increase-early-143000008.html

Culturing DRG Neurons

In our last backstory, we featured Dr. Matt Ramer and the excellent work he and his team are doing on  Sensory Neuron Regeneration. One of the focal points of this research is on the Dorsal Root Ganglion. This is the connection point between the Peripheral Nervous System and Spinal Cord. From the spinal cord signals are sent to the brain for processing.

In response to the expressed needs of our colleagues and customers, we now offer E18 primary Rat DRG tissue

DRGs culture on calf skin collagen

DRGs culture on calf skin collagen

and related methods enabling researchers to make healthy and pure cultures of DRG Neurons.

 Primary Rat DRGs are live neurons isolated from micro-surgically dissected regions of day 18 embryonic Sprague/Dawley rat brain. These cells are prepared fresh each week and shipped in a nutrient rich medium that keeps the cells alive for up to 14 days under refrigeration.

Please note: It is important to review Protocol/Datasheet prior to ordering. There is a unique step for making the dissociation enzyme solution. Do not hesitate to call or e-mail me (612-801-1007 or pshuster@neuromics.com) should you have questions.

References: A dissection and Tissue Culture Manual of the Nervous System (1989). A. Shahar, J.D. Vellis, A. Vernadakis, B. Haber (Eds.), Dissociated Spinal Cord – Dorsal Root Ganglion Cultures on Plastic Tissue Culture Dishes and Glass Coverslips and Wells (pp.219-222). Wiley-Liss, Inc. J.L. Werth,
S.A. Thayer (1994) Mitrochondria Buffer Physiological Calcium Loads in Cultured Rat Dorsal Root Ganglion Neurons, The Journal of Neuroscience, 14(1), 348-356

Dr. Matthew Ramer, Neural Regeneration and SCI

Dr. Matthew Ramer

Dr. Matthew Ramer

I dream of the day that people suffering from spinal cord injuries (SCIs) will be restored to full function. The good news is there are researchers and dedicated centers that form the back-bone of SCI repair research.

I am excited and honored to be featuring Dr. Matthew Ramer for this month’s backstory. Matt is a member of ICORD (International Collaboration On Repair Discoveries) at the University of British Columbia. ICORD is an interdisciplinary research centre for the development of effective strategies to promote functional recovery after spinal cord injury. This includes  the discovery and implementation of relevant solutions to improve functional recovery, mobility, community integration and quality of life for people with spinal cord injury.

Matt’s research focus is on the molecular biology of primary sensory nerve cells (neurons). These neurons are responible for sensation. These include touch, pain, temperature, etc. These neurons transmit sensation to the brain via the spinal cord. It is this transmission that enables us to process the sensation. Similar transmissions happen in the case of locomotion.

Matt’s research helps us better understand the mechanism of these transmissions. More importantly, his work includes finding ways to regenerate and repair neurons. These are steps in improving the outcome of sufferes of SCI.

Making Gains on Pain

Nicolas Beaudet

Nicolas Beaudet

Neuromics has been helping researchers make “gains on pain” from day one. Our initial sales were Opioid Receptor Antibdies licensed from Dr. Robert Elde’s lab at the University of Minnesota.

From this start, we have expanded our expertise and products. Our reputation in this area has resulted in our forming collaborations and friendships with research teams doing important work in chronic and nociceptive pain research.

Over the past several years, I have worked closely with Dr. Nicolas Beaudet, a member of Dr. Philippe Sarret’s team, at the University of Sherbrooke”. In our next backstory we will feature the vangaurd work they are doing on the Neurotensin (NTS) Receptors and pain.

Manipulation of these receptors-NTS-1, NTS-2 and NTS-3 could represent a therapy for pain independent of the opioid pathway. This means pain could be treated without narcotics meaning a reduction of side effects from current treatments including addiction to pain killers.

Dr. Steve Stice Podcast

Inteview with Steve Stice.

Podcast by ClearCast

This Podcast gives is a good primer on Embryonic Stem Cells (ESCs)…where they come from, how they are used and the promise they have for helping researchers cure human diseases.

The listener will gain insight how ECSs when manipulated into mature neuronal cell lines can accelerate the pace of neurological research for scientists working on treatments for spinal cord injuries and neurological diseases such as Parkinson’s, Huntington’s, Alzheimer’s, ALS and possibly even depression.

On Deck-Dr. Steve Stice

We read about the promise of stem cells in the news every day. They could prove to be ”magic bullets” for curing diseases like Alzheimer’s. Parkinson’s, MS and others. Stem Cell Research is also surrounded with controversy as currently cells are often harvested from human embryos and fetuses.I believe top researchers will prove to be the voice of reason in the human stem cell debate as they are the ones best positioned to know the risks, limitations and potential.  

For our August Profile, I am honored to be featuring Dr. Steve Stice. I have had the pleasure of working with Dr. Stice both in his role as Professor and Director of the Regenerative Bioscience Center and Research Alliance Eminent Scholar endowed Chair at the University of Georgia and as Founder and Chief Scientific Officer at Aruna Biomedical.

He has over 16 years of research and development experience in biotechnology and is a co-founder of five biotechnology companies.  He was named one of the 100 Most Influential Georgians by Georgia Trend magazine.  He produced the first cloned rabbit in 1987 and the first cloned transgenic calves in 1998 (George and Charlie).  In 1997 his group produced the first genetically modified embryonic stem cell derived pigs and cattle.  This research led to publications in Science and Nature journals, national news coverage (CBS, NBC, ABC and CNN) and the first US patents on cloning animals and cattle embryonic stem cells.  In 2001, Dr. Stice announced the first cloned animal (calf) from an animal that was dead for 48 hours.  In 2005, his stem cell group published the first work on deriving motor neurons from stem cells.  Motor neurons are damaged lost during the progression of several diseases such as ALS and spinal muscular atrophy.  Throughout his career he has published and lectured on cloning and stem cell technologies.  Prior to joining the University of Georgia, Dr. Stice was a co-founder and Chief Scientific Officer at Advanced Cell Technology, a company developing cloning and stem cell technology.

Here is What is  Currently Hot in the Stice Lab:
New neural stem cells technology developed in my lab was transferred to a commercial entity, Aruna biomedical. This is the first commercialized product derived from human embryonic stem cell using federally approved stem cell lines.

  • We have produced neurons that have neural functions
  • We are working with the Navy to use our neural cells as biosensors for environmental toxins 
  • We have vascular stem cells that have characteristics that may make them suitable for  transplantation
  • We collaborate with a new company call Aruna BioMedical  that will stem cells for neural research and drug discovery
  • Developed a method to test new compounds for Alzheimer’s disease using our neural stem cell
  • We are one of five NIH stem cell training centers and have taught Scientists from Georgia to Bombay India new stem cell techniques
  • In Georgia, we produced over 50 cloned calves and 100 cloned pigs.
  • We were also the first to produce a clone from an animal that had been dead for 48 hours. This opens new opportunities in agriculture and preserving endangered species. 

Dr. Behlke’s 27mer DsiRNA Story Coming Soon

Learn the News Behind the News on 27mer DsiRNA. Includes the story of the how the potentcy of 27mer siRNA was discovered and exiting developments regarding the understanding of the role of the Dicer Complex and RISC. Also featured will be advances in 27mer oligo design and how the technology is being used in basic research and drug discovery.

Here’s a publication highlighting the roots of the story:

Dong Ho Kim, Mark Behlke, Scott Rose, Mi-Sook Chang, Sangdun Choi & John Rossi. Synthetic dsRNA Substrates Enhance RNAi Potency and Efficacy Nature Biotechnology. Published online 26 December 2004;doi10.1038/nbt1051.